The PE Ratio as of September 2024 (TTM) for Cyclerion Therapeutics, Inc. (CYCN) is -0.68

According to Cyclerion Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.68. This represents a change of -17.10% compared to the average of -0.82 of the last 4 quarters.

Cyclerion Therapeutics, Inc. (CYCN) Historical PE Ratio (quarterly & annually)

How has CYCN PE Ratio performed in the past?

The mean historical PE Ratio of Cyclerion Therapeutics, Inc. over the last ten years is -2.03. The current -0.68 PE Ratio has changed 3.26% with respect to the historical average. Over the past ten years (40 quarters), CYCN's PE Ratio was at its highest in in the September 2023 quarter at 0.28. The PE Ratio was at its lowest in in the December 2018 quarter at -55.22.

Cyclerion Therapeutics, Inc. (CYCN) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Cyclerion Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cyclerion Therapeutics, Inc. (CYCN) Average PE Ratio

How has CYCN PE Ratio performed in the past?

The current PE Ratio of Cyclerion Therapeutics, Inc. (CYCN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Cyclerion Therapeutics, Inc. (CYCN) PE Ratio vs. Peers

How is CYCN’s PE Ratio compared to its peers?

Cyclerion Therapeutics, Inc.’s PE Ratio is less than Kronos Bio, Inc. (-0.58), greater than Larimar Therapeutics, Inc. (-8.80), greater than Addex Therapeutics Ltd (-81.79), less than Achilles Therapeutics plc (-0.45), less than Lipella Pharmaceuticals Inc. (-0.00), less than Senti Biosciences, Inc. (-0.23), less than Fennec Pharmaceuticals Inc. (54.24), greater than Monopar Therapeutics Inc. (-1.18), less than Applied Molecular Transport Inc. (-0.14), greater than Cardio Diagnostics Holdings, Inc. (-0.75), greater than Sigilon Therapeutics, Inc. (-1.90), less than Sonnet BioTherapeutics Holdings, Inc. (-0.55), less than ZyVersa Therapeutics, Inc. (-0.10), less than X4 Pharmaceuticals, Inc. (7.41), greater than Axcella Health Inc. (-10.73), less than Magenta Therapeutics, Inc. (-0.04), less than Kezar Life Sciences, Inc. (-0.41), less than ContraFect Corporation (-0.11), greater than ZIVO Bioscience, Inc. (-2.46), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than Erasca, Inc. (-3.94), less than Forte Biosciences, Inc. (-0.39),

Build a custom stock screener for Cyclerion Therapeutics, Inc. (CYCN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cyclerion Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cyclerion Therapeutics, Inc. (CYCN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cyclerion Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.